Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer
Not Applicable
- Conditions
- Patients with postmenopausal ER-positive advanced recurrent breast cancer
- Registration Number
- JPRN-UMIN000015168
- Lead Sponsor
- Japan Breast Cancer Research Group(JBCRG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 710
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients not agree with this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effects of clinical background and prior therapies on the treatment time with Fulvestrant (TTF)
- Secondary Outcome Measures
Name Time Method Secondary analysis <br>1.Effects of clinical background and prior therapies on overall survival (OS) after start of Fulvestrant<br>2.Descriptive statistics of treatment<br>3.Summary of therapies administered to subjects with long survival